Lymphoma Drug Development Strategies at Work

Summary

This report includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma and Lymphoma (general)). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
• Assisting you to make informed decisions in selecting lymphoma sub-indications that are known to be appropriate for your drug's properties
• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
• Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lymphoma therapeutic drug to ensure that the optimal market conditions exist by the time the product is commercialized.

Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents
4.1 List of Figures
4.2 List of Tables

5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment
6.1.1 Carboxy-lyase Activity Targets
6.1.2 Catalytic Activity Targets
6.1.3 Cell Adhesion Molecule Activity Targets
6.1.4 Chaperone Activity Targets
6.1.5 Cysteine-Type Peptidase Activity Targets
6.1.6 Cytokine Activity Targets
6.1.7 DNA Binding Targets
6.1.8 DNA Repair Protein Targets
6.1.9 DNA Topoisomerase Activity Targets
6.1.10 DNA-Directed DNA Polymerase Activity Targets
6.1.11 Glutathione Transferase Activity Targets
6.1.12 G-Protein Coupled Receptor Activity Targets
6.1.13 Growth Factor Activity Targets
6.1.14 Hormone Activity Targets
6.1.15 Hydrolase Activity Targets
6.1.16 Kinase Activity Targets
6.1.17 Kinase Regulator Activity Targets
6.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
6.1.19 Ligase Activity Targets
6.1.20 Lipid Kinase Activity Targets
6.1.21 Lipid Phosphatase Activity Targets
6.1.22 MHC Class I Receptor Activity Targets
6.1.23 Molecular Function Unknown Targets
6.1.24 Motor Activity Targets
6.1.25 Oxidoreductase Activity Targets
6.1.26 Phosphorylase Activity Targets
6.1.27 Protein Binding Targets
6.1.28 Protein Serine/Threonine Kinase Activity Targets
6.1.29 Protein Tyrosine Phosphatase Activity Targets
6.1.30 Protein-Tyrosine Kinase Activity Targets
6.1.31 Receptor Activity Targets
6.1.32 Receptor Binding Targets
6.1.33 Receptor Signaling Complex Scaffold Activity Targets
6.1.34 RNA Binding Targets
6.1.35 Serine-Type Peptidase Activity Targets
6.1.36 Structural Constituent Of Cytoskeleton Targets
6.1.37 Superoxide Dismutase Activity Targets
6.1.38 T Cell Receptor Activity Targets
6.1.39 Transcription Factor Activity Targets
6.1.40 Transcription Regulator Activity Targets
6.1.41 Translation Regulator Activity Targets
6.1.42 Transmembrane Receptor Activity Targets
6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.1.44 Transporter Activity Targets
6.1.45 Other Targets
6.2 The Cancer Genome Project and Lymphoma Targets
6.2.1 Lymphoma Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.3 Structure-based Drug Design in Lymphoma is Stimulated by Available Structure Data on Biological Targets
6.4 Target-Target Interactions among Identified Lymphoma Targets
6.5 The Drug-Target Interactome
6.6 Protein Expression Levels of Identified Drug Targets of Lymphoma Drugs
6.7 Pathway Analysis of Lymphoma Drug Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline?
7.1 Terminated Drug Target Profiles in Lymphoma
7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lymphoma Pipeline
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lymphoma Pipeline
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline
7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline
7.7 Development Profiles of All Lymphoma Drug Target Profiles

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound
8.1 Small Molecules
8.1.1 Background
8.1.2 Targets in Lymphoma
8.2 Peptide/Protein Drugs
8.2.1 Background
8.2.2 Targets in Lymphoma
8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Targets in Lymphoma
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Targets in Lymphoma
8.5 Gene Therapy
8.5.1 Background
8.5.2 Targets in Lymphoma
8.6 The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma
8.7 Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets

9 Selecting a Sub-Indication of Lymphoma for Drug Development
9.1 B-cell Lymphoma
9.1.1 Players and their Compared Pipeline
9.1.2 Where is the Real Competition?
9.1.3 How Successful are They in Their Targeting Strategy?
9.2 Hodgkin's Lymphoma
9.2.1 Players and their Compared Pipeline
9.2.2 Where is the Real Competition?
9.2.3 How Successful are They in Their Targeting Strategy?
9.3 Lymphoma (general)
9.3.1 Players and their Compared Pipeline
9.3.2 Where is the Real Competition?
9.3.3 How Successful are They in Their Targeting Strategy?
9.4 Non-Hodgkin's Lymphoma
9.4.1 Players and their Compared Pipeline
9.4.2 Where is the Real Competition?
9.4.3 How Successful are They in Their Targeting Strategy?
9.5 T-cell Lymphoma
9.5.1 Players and their Compared Pipeline
9.5.2 Where is the Real Competition?
9.5.3 How Successful are They in Their Targeting Strategy?

10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator351
10.1 Abbott
10.2 Abiogen
10.3 AEgera
10.4 Aeterna Zentaris
10.5 Affimed Therapeutics
10.6 Aida Pharmaceuticals
10.7 Alfa Wassermann
10.8 Alfacell
10.9 Allos Therapeutics
10.10 Amgen
10.11 Anadys Pharmaceuticals
10.12 Antigenics
10.13 Archer Biosciences
10.14 Ariad
10.15 Ascenta Therapeutics
10.16 Astellas
10.17 AstraZeneca
10.18 Attenuon
10.19 AVEO
10.20 Benitec
10.21 BioCryst Pharmaceuticals
10.22 Biogen Idec
10.23 Biolex
10.24 Boehringer Ingelheim
10.25 Borean Pharma
10.26 Bristol-Myers Squibb
10.27 BTG
10.28 Calistoga Pharmaceuticals
10.29 Cell Therapeutics
10.30 Cephalon
10.31 Cyclacel
10.32 Cylene Pharmaceuticals
10.33 Cytokinetics
10.34 Daiichi Sankyo
10.35 Dainippon Sumitomo Pharma
10.36 Dara Biosciences
10.37 Dynavax Technologies
10.38 Eisai
10.39 Eli Lilly
10.40 Enzon
10.41 EpiCept
10.42 Exelixis
10.43 Favrille
10.44 Gemin X Pharmaceuticals
10.45 Genentech
10.46 Genmab
10.47 GenPat77
10.48 Genta
10.49 Genzyme
10.50 GlaxoSmithKline
10.51 Gloucester Pharmaceuticals
10.52 Hayashibara
10.53 Hoffmann-La Roche
10.54 Human Genome Sciences
10.55 Hy BioPharma
10.56 ImClone Systems
10.57 Immunomedics
10.58 Inex
10.59 Innate Pharma
10.60 InNexus Biotechnology
10.61 Intracel
10.62 Italfarmaco
10.63 Johnson & Johnson
10.64 Kissei
10.65 Kyowa Hakko Kirin
10.66 Ligand
10.67 Lorus Therapeutics
10.68 MacroGenics
10.69 Meda
10.70 Medarex
10.71 MedImmune
10.72 MethylGene
10.73 Micromet
10.74 Nektar Therapeutics
10.75 National Institute of Health (USA)
10.76 Novartis
10.77 Oncothyreon
10.78 Pfizer
10.79 Pharmacyclics
10.80 PharmaMar
10.81 ProNAi Therapeutics
10.82 Reata Pharmaceuticals
10.83 Rigel
10.84 Sanofi-Aventis
10.85 Santaris Pharma
10.86 SBIO
10.87 Seattle Genetics
10.88 Shire
10.89 SuperGen
10.90 Takeda
10.91 Telik
10.92 Titan Pharmaceuticals
10.93 TopoTarget
10.94 Transgene
10.95 Trubion
10.96 Vaccinex
10.97 Vertex Pharmaceuticals
10.98 VGX Pharmaceuticals
10.99 Vion Pharmaceuticals
10.100 VioQuest
10.101 Wyeth
10.102 Xencor
10.103 Yakult Honsha
10.104 Zenyaku Kogyo
10.105 ZymoGenetics
10.106 Non-industrial Source

11 Disclaimer

12 Drug Index

13 Company Index

List of Figures
Figure 1: Overall Breakdown of the Included Lymphoma Therapeutic Pipeline by Sub-Indication and Stage of Development
Figure 2: Visualization of Target-Target Interactions Among Lymphoma Drug Targets
Figure 3: The Drug-Protein Interactome of Lymphoma Drugs -Clusters I
Figure 4: The Drug-Protein Interactome of Lymphoma Drugs - Clusters II
Figure 5: Head-to-Head Targeting Interactome of Lymphoma Drugs
Figure 6: Distribution of Compound Types among Lymphoma Drugs
Figure 7: Primary Sub-cellular Localization of Drug Targets
Figure 8: Breakdown of the B-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 9: Breakdown of the B-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development
Figure 10: Breakdown of the Hodgkin's Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 11: Breakdown of the Hodgkin's Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development
Figure 12: Breakdown of the Lymphoma (general) Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 13: Breakdown of the Lymphoma (general) Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development
Figure 14: Breakdown of the Non-Hodgkin's Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 15: Breakdown of the Non-Hodgkin's Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development
Figure 16: Breakdown of the T-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development
Figure 17: Breakdown of the T-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development

List of Tables
Table 1: Competitive Pressure Force Among Lymphoma Drugs
Table 2: Overview of Drug Target Profile Themes
Table 3: Drug Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 4: Identity of Lymphoma Drug Targets with Available Biological Structures
Table 5: Number of Target-Target Interactions among Lymphoma Drug Targets
Table 6: Drug-Protein Interactome Clusters
Table 7: Lymphoma Drug Targets with Available Protein Expression Profiles
Table 8: Pathway Summary
Table 9: Drug Targets without any Identified Assigned Pathways
Table 10: Pathway Profile According to BioCarta of Lymphoma Drug Targets
Table 11: Pathway Profile According to KEGG of Lymphoma Drug Targets
Table 12: Pathway Profile According to NetPath of Lymphoma Drug Targets
Table 13: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness
Table 14: Top Competitive Lymphoma Target Profiles
Table 15: Terminated Drug Target Profiles in Lymphoma
Table 16 New and Unique Lymphoma Targets in Pre-Registration to Marketed
Table 17: New and Unique Lymphoma Targets in Phase III Clinical Development
Table 18: New and Unique Lymphoma Targets in Phase II Clinical Development
Table 19: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs
Table 20 New and Unique Lymphoma Targets in Phase I Clinical Development
Table 21: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs
Table 22: New and Unique Lymphoma Targets in Preclinical Development
Table 23: The Progression, Maturity and Competitive Comparison of Lymphoma Drug Target Profiles in Development
Table 24: Overview of Compound Strategy Competition in Lymphoma
Table 25:Overview of the Competitive Landscape of Small Molecular Drugs in Lymhpoma
Table 26: Head-to-head Target Competing Small Molecule Drugs for the Treatment of Lymphoma
Table 27: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lymphoma
Table 28: The Progression, Maturity and Competitive Comparison of Small Molecule Lymphoma Drug Target Profiles in Development
Table 29: The Progression, Maturity and Competitive Comparison of Peptide Based Lymphoma Drug Target Profiles in Development
Table 30:Overview of the Competitive Landscape of Protein Based Drugs in Lymhpoma
Table 31: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lymphoma
Table 32: The Progression, Maturity and Competitive Comparison of Protein Based Lymphoma Drug Target Profiles in Development
Table 33:Overview of the Competitive Landscape of Antibody Drugs in Lymhpoma
Table 34: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lymphoma
Table 35: The Progression, Maturity and Competitive Comparison of AntibodyLymphoma Drug Target Profiles in Development
Table 36:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lymhpoma
Table 37: The Progression, Maturity and Competitive Comparison of Nucleic Acid Lymphoma Drug Target Profiles in Development
Table 38: Vectors in Gene Therapy
Table 39: The Progression, Maturity and Competitive Comparison of Gene Therapy Lymphoma Drug Target Profiles in Development
Table 40: The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma
Table 41: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets
Table 42: Competitive Summary of Lymhpoma Drugs by Sub-Indication
Table 43: Players in the Field of B-cell Lymphoma Drug Development and their Compared Pipeline
Table 44: The Competition Through Close Mechanistic Approximation Between B-cell Lymphoma Drugs
Table 45: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in B-cell Lymphoma Drug Development
Table 46: Players in the Field of Hodgkin's Lymphoma Drug Development and their Compared Pipeline
Table 47: The Competition Through Close Mechanistic Approximation Between Hodgkin's Lymphoma Drugs
Table 48: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Hodgkin's Lymphoma Drug Development
Table 49: Players in the Field of Lymphoma (general) Drug Development and their Compared Pipeline
Table 50: The Competition Through Close Mechanistic Approximation Between Lymphoma (general) Drugs
Table 51: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lymphoma (general)Drug Development
Table 52: A) Investigators with Multiple Non-Hodgkin's Lymphoma Drugs in Development B) Investigators with Ceased, Discontinued or Suspended Drugs
Table 53: Players in the Field of Non-Hodgkin's Lymphoma Drug Development and their Compared Pipeline
Table 54: The Competition Through Close Mechanistic Approximation Between Non-Hodgkin's Lymphoma Drugs
Table 55: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Hodgkin's Lymphoma Drug Development
Table 56: Players in the Field of T-cell Lymphoma Drug Development and their Compared Pipeline
Table 57: The Competition Through Close Mechanistic Approximation Between T-cell Lymphoma Drugs
Table 58: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in T-cell Lymphoma Drug Development
Table 59: Abbott's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 60: Abiogen's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 61: AEgera's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 62: Aeterna Zentaris' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 63: Affimed Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 64: Aida Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 65: Alfa Wassermann's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 66: Alfacell's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 67: Allos Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 68: Amgen's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 69: Anadys Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 70: Antigenics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 71: Archer Biosciences' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 72: Ariad's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 73: Ascenta Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 74: Astellas' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 75: AstraZeneca's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 76: Attenuon's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 77: AVEO's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 78: Benitec's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 79: BioCryst Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 80: Biogen Idec's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 81: Biolex's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 82: Boehringer Ingelheim's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 83: Borean Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 84: Bristol-Myers Squibb's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 85: BTG's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 86: Calistoga Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 87: Cell Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 88: Cephalon's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 89: Cyclacel's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 90: Cylene Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 91: Cytokinetics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 92: Daiichi Sankyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 93: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 94: Dara Biosciences' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 95: Dynavax Technologies' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 96: Eisai's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 97: Eli Lilly's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 98: Enzon's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 99: EpiCept's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 100: Exelixis' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 101: Favrille's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 102: Gemin X Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 103: Genentech's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 104: Genmab's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 105: GenPat77's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 106: Genta's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 107: Genzyme's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 108: GlaxoSmithKline's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 109: Gloucester Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 110: Hayashibara's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 111: Hoffmann-La Roche's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 112: Human Genome Sciences' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 113: Hy BioPharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 114: ImClone Systems' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 115: Immunomedics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 116: Inex's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 117: Innate Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 118: InNexus Biotechnology's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 119: Intracel's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 120: Italfarmaco's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 121: Johnson & Johnson's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 122: Kissei's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 123: Kyowa Hakko Kirin's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 124: Ligand's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 125: Lorus Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 126: MacroGenics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 127: Meda's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 128: Medarex's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 129: MedImmune's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 130: MethylGene's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 131: Micromet's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 132: Nektar Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 133: National Institute of Health (USA)'s Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 134: Novartis' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 135: Oncothyreon's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 136: Pfizer's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 137: Pharmacyclics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 138: PharmaMar's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 139: ProNAi Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 140: Reata Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 141: Rigel's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 142: Sanofi-Aventis' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 143: Santaris Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 144: SBIO's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 145: Seattle Genetics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 146: Shire's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 147: SuperGen's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 148: Takeda's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 149: Telik's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 150: Titan Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 151: TopoTarget's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 152: Transgene's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 153: Trubion's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 154: Vaccinex's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 155: Vertex Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 156: VGX Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 157: Vion Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 158: VioQuest's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 159: Wyeth's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 160: Xencor's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 161: Yakult Honsha's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 162: Zenyaku Kogyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 163: ZymoGenetics' Included Lymphoma Pipeline Composition and Competitive Fall-Out
Table 164: Non-industrial source's Included Lymphoma Pipeline Composition and Competitive Fall-Out